Active, not recruitingPhase 3NCT05881408

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

Studying Duchenne muscular dystrophy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sarepta Therapeutics, Inc.
Principal Investigator
Medical Director
Sarepta Therapeutics, Inc.
Intervention
delandistrogene moxeparvovec(genetic)
Enrollment
148 enrolled
Eligibility
MALE
Timeline
20232027

Study locations (20)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05881408 on ClinicalTrials.gov

Other trials for Duchenne muscular dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Duchenne muscular dystrophy

← Back to all trials